Looking Into Vertex Pharmaceuticals's Recent Short Interest
Decoding 7 Analyst Evaluations For United Therapeutics
Goldman's 'Buyback' Basket: CMCSA, GM, MPC, Etc
Goldman's High Growth Investment Ratio Stocks: EA, AMZN, FANG, Etc
United Therapeutics Analyst Ratings
Sarepta a New Buy at Jefferies on Muscular Dystrophy Franchise, Pipeline
Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
Gilead Upgraded to Outperform by Leerink on PreEP Outlook
Peering Into Gilead Sciences's Recent Short Interest
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
AbbVie Announces That 9 Canadian Provinces Have Provided Accelerated Public Coverage Of EPKINLY, A Treatment For Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma
Unveiling 15 Analyst Insights On Sarepta Therapeutics
HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $600 Price Target
Vertex Pharmaceuticals Analyst Ratings
Sarepta Therapeutics Analyst Ratings
AbbVie Says Latest FDA Approval Expands Botox Use Beyond Face
Market Whales and Their Recent Bets on VRTX Options
Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today